Caribou Biosciences, Inc.
CRBU · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $2 | $3 | $2 | $2 |
| % Growth | -17.6% | 13.3% | 13.3% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $30 |
| Gross Profit | $2 | $3 | $2 | -$28 |
| % Margin | 71.3% | 100% | 100% | -1,337.8% |
| R&D Expenses | $22 | $28 | $36 | $30 |
| G&A Expenses | $0 | $10 | $10 | $10 |
| SG&A Expenses | $9 | $10 | $10 | $10 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $12 | $0 | -$30 |
| Operating Expenses | $31 | $50 | $45 | $11 |
| Operating Income | -$29 | -$48 | -$43 | -$39 |
| % Margin | -1,337.6% | -1,784% | -1,823.8% | -1,871.7% |
| Other Income/Exp. Net | $2 | -$7 | $3 | $3 |
| Pre-Tax Income | -$28 | -$54 | -$40 | -$35 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$28 | -$54 | -$40 | -$35 |
| % Margin | -1,253.3% | -2,028.4% | -1,699.6% | -1,708.7% |
| EPS | -0.3 | -0.58 | -0.43 | -0.39 |
| % Growth | 48.3% | -34.9% | -10.3% | – |
| EPS Diluted | -0.3 | -0.58 | -0.43 | -0.39 |
| Weighted Avg Shares Out | 93 | 93 | 93 | 90 |
| Weighted Avg Shares Out Dil | 93 | 93 | 93 | 90 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$27 | -$34 | -$42 | -$37 |
| % Margin | -1,224.6% | -1,284.6% | -1,774.2% | -1,785.8% |